Phase I Study of Cabazitaxel- PF Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

ID Number 11-0646

Principal Investigator(s)
Krzysztof J Misiukiewicz

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to collect information on the safety of Cabazitaxel and to learn how effective Cabazitaxel is in combination with Cisplatin and Fluorouracil in treating your type of cancer. Information from other research studies suggests that Cabazitaxel decreases the growth of tumor cells which are ultimately destroyed.

The use of Cabazitaxel in this trial is called investigational because it is not approved for use in the treatment of head and Neck cancer. Cabazitaxel is already approved by the Food and Drug Administration (FDA) for the treatment of Prostate cancer.

You may qualify to take part in this research study because you have cancer of head and neck.

Contact Information

Recruiting Patients: No